ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

25 Jul 2024 13:05:00 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

12 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Adagene to Present at Investor Conferences in June

22 May 2024 13:45:00 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

29 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

07 Mar 2024 13:01:00 By Nasdaq GlobeNewswire

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

27 Feb 2024 05:00:01 By Nasdaq GlobeNewswire

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

09 Feb 2024 03:00:00 By Nasdaq GlobeNewswire

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

16 Jan 2024 14:01:00 By Nasdaq GlobeNewswire

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

04 Jan 2024 02:00:00 By Nasdaq GlobeNewswire

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

03 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

12 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Adagene to Present at Investor and Scientific Conferences in September

07 Sep 2023 03:00:00 By Nasdaq GlobeNewswire

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

31 Aug 2023 04:32:21 By Nasdaq GlobeNewswire

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

04 May 2023 06:00:01 By Nasdaq GlobeNewswire

Adagene Announces Updates to its Board of Directors

28 Apr 2023 04:00:11 By Nasdaq GlobeNewswire

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

18 Apr 2023 06:17:47 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

28 Mar 2023 13:30:06 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

14 Mar 2023 15:00:00 By Nasdaq GlobeNewswire

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

05 Mar 2023 16:39:30 By Nasdaq GlobeNewswire

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

09 Jan 2023 04:00:01 By Nasdaq GlobeNewswire